Robert E. Waltermire, Senior VP, Chief Pharma Development at MADRIGAL PHARMACEUTICALS, INC. (MDGL), sold 15,800 shares at $275.53 ($4.3M) on 2023-03-01, disclosed to the SEC on 2023-03-02.
Open-market sale of $4.3M MDGL by Senior VP, Chief Pharma Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $271.03 | 900 | $244K | 5.6% |
| 2 | $271.03 | 900 | $244K | 5.6% |
| 3 | $272.30 | 4,100 | $1.1M | 25.8% |
| 4 | $273.44 | 1,928 | $527K | 12.2% |
| 5 | $273.44 | 1,928 | $527K | 12.2% |
| 6 | $274.57 | 1,672 |
| $459K |
| 10.6% |
| 7 | $274.57 | 1,672 | $459K | 10.6% |
| 8 | $275.53 | 1,300 | $358K | 8.3% |
| 9 | $275.53 | 1,300 | $358K | 8.3% |
| 10 | $276.19 | 100 | $28K | 0.6% |
| Total | $273.47 avg | 15,800 | $4.3M | 100% |
| Filing → |
| MDGL | SELL | 2025-01-27 | $35K | — | Filing → |
| MDGL | SELL | 2025-01-17 | $242K | — | Filing → |
| MDGL | SELL | 2024-06-18 | $532K | — | Filing → |